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Stereoselective formation of chiral metallopeptides 
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Despite the enormous growth of chemical biology over the last 
decade, the contributions of coordination and 
metallosupramolecular chemistry in this area remain relatively 
scarce.[1] One possible reason for this underdevelopment is that 
the chemical differences between biomolecules and typical 
ligands hamper the integration of metal complexes into biological 
systems.[2] In this context, peptides could be particularly attractive 
templates for the design of biologically friendly coordination 
compounds that integrate precise structural and biofunctional 
properties encoded by the amino acid sequence of the peptide 
ligands.[3] Furthermore, the stereoselective formation of chiral 
complexes is of fundamental interest in chemical biology, as 
chirality plays a major role in the recognition processes of 
biological target,[4,5] but controlling the metal center configuration 
usually requires demanding synthetic procedures for obtaining 
chiral ligands,[6,7,8] which complicates the access to multiple 
structural variants that are required for the systematic studies 
involved in the optimization of their biological properties. 
Peptides however, being intrinsically chiral, are ideal platforms 
for controlling the configuration of their derived asymmetric 
metal complexes. In addition to that, the fast and robust solid 
phase peptide synthesis (SPPS) methods allow their assembly and 
optimization with a simplicity and flexibility unmatched by 
classic organic synthetic procedures in solution.[9]  
Metalloproteins exploit the protein architecture to carefully 
position the amino acid side chains in order to create appropriate 
coordination environments[ 10 ] This can also be achieved in 
synthetic molecules by using unnatural metal-chelating amino 
acids that simultaneously orient more than one donor atom. Thus, 
it is known that the 2,2’-bipyridine (Bpy) ligand leads to stable 
complexes with many metal ions and as such, it is one of the most 
commonly used binding units in coordination and supramolecular 
chemistry.[11] However, there are still very few examples of 
bipyridine-based metallopeptides in the literature. In most reports 
the Bpy units are attached to the N-terminal end of the peptide 
sequence,[12] or located at the side chain of an unnatural amino 
acid,[13] but there are only a handful of examples in which the Bpy 
units are incorporated as part of the peptide backbone.[14]  
Herein we report a straightforward approach to control the 
chirality or peptide metal complexes. Our strategy takes 
advantage of standard SPPS methodsfor fast and efficient access 
to simple linear Bpy-based peptide ligands, and exploits the 
strong coupling between the conformational preferences of the 
peptide chain with the coordination geometry of the metal centres 
to control of the configuration of the resulting peptide complexes.  
The Bpy unit was derivatized with 5-amino-3-oxapentanoic 
acid (O1Pen) as a Fmoc-protected achiral amino acid for solid 
phase peptide synthesis (Fmoc-O1PenBpy-OH 5). Starting from 
the commercial 5,5’-dimethy-2,2’-bipyridine 1, and following a 
modified procedure from earlier reports,[14a,15] we were able to 
design and optimize the synthesis of 5 in multigram scale with an 
overall yield of 46%. In short, after initial oxidation and 
esterification, the Bpy was desymmetrized by taking advantage of 
the poor solubility of its monocarbohydrazide (2). Curtius 
rearrangement of the corresponding carbazide, and subsequent 
deprotection of intermediate 3, afforded the desired Bpy amino 
acid core unit 4. Given the poor reactivity of aromatic amines in 
peptide couplings,[14a,16] the core Bpy amino acid 4 was coupled 
with 5-amino-3-oxapentanoic acid (O1Pen) to give the desired 
final building block (5 Scheme 1), which displayed good 
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solubility and reactivity for performing solid phase coupling 
reactions under standard conditions. 
 
Scheme 1. Synthesis of the 2,2’-bipyridine amino acid (4), and its derivative for 
SPPS, Fmoc-O1PenBpy-OH (5). 
Following the synthesis of 5, and based on preliminary 
molecular modeling studies,[17] we designed a number of peptide 
ligands featuring two Bpy coordinating units joined by short 
linkers containing between 3 and 5 amino acid residues (Table 1, 
P3-P5). These include a Pro-Gly β-turn promoting sequence that 
would preorganize the peptide chain and promote metal chelation, 
thus avoiding the formation of polymeric peptide complexes in 
the presence of metal ions.[18] In addition to the conformational 
restrictions imposed by the Pro residue, we expected that 
introducing D-Pro or L-Pro residues for the synthesis of 
enantiomeric peptide ligands would allow the control the chirality 
of the resulting metal complexes. Peptides were synthesized 
following standard Fmoc/tBu solid-phase protocols,[14b,c,19] and 
purified by reverse-phase HPLC. 
 
Scheme 2. Solid phase peptide synthesis of bis-Bpy peptide ligands D-P3 and L-P3, 
and its metal complexes. Introduction of D-Pro or L-Pro residues in the loop selects a 
particular chirality. Numbering scheme used in the NMR discussion below is showed 
in grey. 
Incubation of 13 µM solutions of the three L-peptide ligands  
(L-P3, L-P4, L-P5) in PBS buffer (pH = 5.6, 298 K) with Co(II) 
resulted in clear bathochromic shifts of the Bpy absorption band 
due to the complexation processes, from 309 nm in the free 
ligands to 322 nm in their metal complexes. The spectroscopic 
changes displayed by the three peptides upon incubation under the 
same conditions with Ni(II), which has higher tendency than 
Co(II) to form octahedral complexes, and with Zn(II), which 
forms diamagnetic complexes suitable for perform NMR studies 
in solution, were qualitatively very similar to those observed for 
Co(II). 
Table 1. Peptide ligands synthesized in this study. 
Peptide[a] Sequence 
  L-P3 H-O1PenBpy-Gly- L-Pro -Gly-O1PenBpy-Gly-NH2 
  D-P3 H-O1PenBpy-Gly- D-Pro -Gly-O1PenBpy-Gly-NH2 
  L-P4 H-O1PenBpy-Gly-Gly- L-Pro -Gly-O1PenBpy-Gly-NH2 
  L-P5 H-O1PenBpy-Gly-Gly-Gly- L-Pro -Gly-O1PenBpy-Gly-NH2 
[a] Loop sequences are highlighted in italics. All peptides were synthesized as N-
terminal free amine and C-terminal amide. 
Table 2. Stability constants of peptides L-P3, L-P4, L-P5 complexes with selected 
metal ions in PBS, pH 5.6 at 298 K. 
Peptide Logβm,n[a] Co(II) Ni(II) Zn(II) 



























[a] Loop sequences are highlighted in italics. All peptides were synthesized as N-
terminal free amine and C-terminal amide. 
The binding constants derived from the UV/vis titrations are 
summarized in Table 2, and indicate that the Co(II) complex with  
L-P3 is the most stable of the series (log β11 = 7.16). Interestingly, 
the best fit to the experimental data suggests an appreciable 
proportion of the 1:2 ML2 species in the initial steps of the 
titration, when the peptide ligand is in greater excess over the 
metal ion. Further increasing in the metal to ligand ratios, 
progressively shifts the equilibrium towards the expected 1:1 
complex later in the titration (Figure 1).  
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Figure 1. UV/Vis titration of 13 µM L-P3 with increasing concentrations of Co(II) 
and best fit to a mixed 1:1 and 1:2 model (solid line). Curves representing the 
relative populations of free L-P3 (L), ML and ML2 complexes are overlaid as dashed 
lines. 
The thermodynamic stabilities of the Ni(II) and Zn(II) 
complexes of L-P3 are about one order of magnitude less stable 
than the Co(II) equivalent (log β11 ≈ 6.75-6.08). The L-P4 metal 
complexes appear only marginally less stable than their L-P3 
analogs but, in contrast, all the L-P5 metallopeptides display 
significantly lower binding constants (log β11 ≈ 5.18-3.33). 
Moreover, the titration profiles of the L-P5 peptides suggest the 
occurrence of higher order species and/or oligomers. Finally, in 
addition to these titrations, the absence of d-d transition bands in 
concentrated solutions of L-P3 with Ni(II) and Co(II) suggest that 
these metals adopt an octahedral configuration as [M(L-
P3)(H2O)2]2+ species, completing their coordination sphere with 
two water molecules. 
Given the renewed significance of chiral coordination 
complexes with biological applications,[5] we were thus 
particularly interested in the effect of the chiral D-Pro and L-Pro 
residues included in the peptide loops. Considering that L-P3 and 
L-P4 form coordination compounds of similar thermodynamic 
stabilities, we decided to focus our attention on the L-P3 peptide, 
because the shorter three-amino acid loop in this ligand should 
impose tighter conformational restrictions than L-P4, and hence 
provide with better chiral induction in the resulting 
metallopeptides.  
At this point, we decided to carry out molecular modeling 
studies in order to gain some insight into the structural features of 
the [Zn(L/D-P3)]2+ complexes and identify the relationship 
between the chirality of the Pro residue and that of the resulting 
metal complex.[20] It has to be noted that the modeling of metal-
mediated recognition processes is still one of the major challenges 
faced by computational chemistry,[21] and there are no reports of 
reliable models of metal complexes derived of highly flexible 
ligands, a tool which could be very useful in 
metallosupramolecular chemistry or in inorganic chemical 
biology. In order to determine the structure of both complexes, 
and because of the presence of non-natural residues, we designed 
and applied a first principle protocol instead of knowledge-driven 
and fragment-based approaches recently reported.[22] Calculations 
were first undertaken to characterize the conformational space of 
the isolated ligands. Large torsional Monte Carlo samplings 
coupled with low energy mode displacements were carried out for 
both D- and L-Pro species.[23] In each case, about 250 minima 
were identified in a window of about 21 kJ·mol−1. The 
conformers presented similar overall tendencies in both 
ensembles, and could be clustered into a reduced number of folds. 
In most, substantial π-π interactions between the two Bpy units 
were observed (see Figure S1, supporting information), and the 
lowest energy conformations presented stronger stacking. Despite 
some variability, the Gly1-Pro-Gly2 loop mainly adopts a turn 
with a hydrogen bond between the carbonyl of the Pro and the 
nitrogen of the Gly2 backbone. Importantly, the asymmetry 
arising from the D-Pro and L-Pro residues appears in the lowest 
energy conformations as a loop in an anti-clockwise configuration 
for the former and a clockwise configuration for the latter.  
The structures of the Zn(II) complexes were obtained by a 
constrained minimization of the lowest energy conformation of 
the isolated ligands towards a tetrahedral geometry of the 
nitrogens in the bipyridine groups,[24] followed by a Quantum 
Mechanical/Molecular Mechanics minimization of the zinc-bound 
complexes (see supplementary information) using the ONIOM 
scheme,[25] as implemented in Gaussian’09.[26] In all the resulting 
structures the π-π interactions have been lost, so that the two Bpy 
units are almost perpendicular, the twist of the Gly1-Pro-Gly2 loop 
has been amplified, and the Pro-Gly2 hydrogen bonding has been 
significantly lost. Importantly, the optimized structure of the D-
Pro and L-Pro systems appear highly symmetric with the metal 
center providing with R and S chirality, respectively (Figure 2). 
Moreover, attempts to obtain inverted metal configurations based 
on alternative low-energy conformations of the ligand were in all 
cases unsuccessful. 
 
Figure 2. Optimized structures of the [Zn(L/D-P3)]2+ complexes. The arrows indicate 
the NOE contacts observed in the NOESY spectrum of [Zn(L-P3)]2+ (600 MHz, 
H2O/D2O PBS buffer, pH 5.6, 280 K, 500 ms mixing time) in the presence of 1.2 
equivalents of ZnSO4, which are not present without the salt. 
Further comparison between the free and metal-bound 
systems show that the conformations adopted by the ligands in the 
complexes are relatively close to the conformations of the free 
ligands in the 21 kJ/mol window from the absolute minima (with 
rmsd lower than 1 Å). The conformational transition of the 
ligands between unbound and bound structures only requires the 
rearrangement of one of the Bpy units, for which the twist of the 
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loop is accentuated  (Figure S1, supporting information). Our 
results show that the chirality of the Pro residue dictates a highly 
asymmetric conformational space of the ligands. This leads to the 
preorganization of the ligands towards conformations that 
apparently condition the chirality of the metal bound systems.[27]  
Zn(II) complexes are diamagnetic and thus suitable for NMR 
studies. This allowed us to make a complete NMR 
characterization of [Zn(L-P3)]2+ in order to validate in solution the 
structure described above. First, the isolated ligand (L-P3) was 
studied (0.2 mM in D2O PBS buffer at pH = 5.6). 1H NMR 
spectral assignment (TOCSY, 25 and 60 ms mixing times, and 
NOESY, 500 ms mixing time, see supporting information) was 
carried out at 280 K. The NOESY spectrum only showed the 
intra-ring cross peaks involving H3 and H4 protons (see 
supporting information) for each pyridine ring as the only NOE 
contact involving aromatic protons. This fact is in agreement with 
previous studies that excluded the presence of a cis disposition of 
the nitrogen atoms in 2,2’-subtituted bipyridines.[28] Fittingly, 
addition of 1.2 equivalents of Zn(II) induced significant chemical 
shift changes of the aromatic protons (Figure 3, panel A), 
indicating a change in their chemical environments, and thus 
suggesting the complexation of the Bpy to the metal center. 
DOSY spectra (see supporting information) excluded the presence 
of oligomers upon these conditions. Moreover, inspection of the 
new NOESY spectra (in H2O and D2O) now recorded revealed a 
new NOE contact in the aromatic region corresponding to an 
inter-ring H3-H3´ contact (Figure 3, panel B). This key cross peak 
strongly supports the existence of a conformational change, from 
trans to cis, around the C-C bond of the bipyridine moieties. 
Additional long range NOEs that were in full agreement with the 
distances estimated for the tetrahedric structure proposed by the 
theoretical calculations (Figure 2 and supporting information) 
were also found. In addition to that, cross peaks between the 
hydrogens in positions 6 and 6’ from the two coordinating Bpy 
units, which would be expected for a hypothetical octahedral 
[Zn(L-P3)(H2O)2]2+ complex, were not observed, further 
supporting the tetrahedral arrangement of the two Bpy units 
around the metal center. These results represent the first detailed 
NMR study of labile Bpy coordination compounds.  
Following the structural characterization of the complexation 
of L-P3, we studied the influence of the chirality of the Pro 
residues by circular dichroism. The CD spectra both L-P3 and D-
P3, as well as the spectra their corresponding metal complexes are 
qualitatively very similar with all the metal ions, and only minor 
variations are observed in the intensity and position of the CD 
bands. As expected, L-P3 and its enantiomer D-P3 give rise to 
mirror image spectra, showing two bands of opposite signs at 
approximately 300 and 330 nm with a crossover at 316 nm. D-P3 
displays a positive Cotton effect and L-P3 a mirror spectrum with 
a negative Cotton effect (Figure 3 and ESI). The intensity of these 
bands increases notably upon addition of metal ions, which also 
experiment a bathochromic shift to 315 and 340 nm. The sign of 
the Cotton effect of the complexes is consistent with a Λ- 
configuration for the D-Pro metallopeptides [M(D-P3)(H2O)2]2+, 
and Δ- configuration for the L-Pro diaquo Co(II) and Ni(II) 
complexes,[ 29 ] and in agreement with the conformational 




Figure 3. a) 1H NMR 600 MHz spectra of L-P3 at 280 K in D2O (PBS buffer, pH 5.6) 
in the absence (bottom spectrum) and presence (top spectrum) of 1.2 equivalents of 
Zn(II) The corresponding aromatic regions are enlarged and the chemical shifts 
changes are annotated. b) Aromatic region of the NOESY spectrum (500 ms mixing 
time) at 280 K in the presence of 1.2 equivalents of Zn(II). 
In summary, we have demonstrated a simple procedure for the 
thermodynamic selection of the supramolecular chirality in 
metallopeptide complexes, as shown by detailed theoretical and 
structural studies, including the first detailed NMR study of a 
labile Bpy coordination compound, the [Zn(l-P3)]2+ complex. This 
strategy should be applicable for the synthesis of bioactive 
peptides with multiple coordinating units and, towards this end, 
ongoing efforts in our group aim at the synthesis and study of tris-
bipiridyl octahedral metallopeptide complexes, as well as 
exploiting the versatility of peptide synthesis for obtaining 
biofunctional complexes. 
 
Figure 4. Dashed lines: Circular Dichroism spectra of a 0.7 mM solution of D-P3 (○) 
and L-P3 (●) in 10 mM PBS buffer pH 5.1. Continuous lines: same solutions after 
addition of 1.3 eq. of Co(II). Absorption spectra of free (dashed line) and coordinated 
L-P3 (solid line) are shown for reference on top of the CD spectra. 
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